HIV medicine · 2026
Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leleux O, Peyrouny-Mazeau A, Perrier A, Hessamfar M, Le Moal G, Neau D, Alleman L, Cazanave C, Lazaro E, Duffau P, Riché A, Gérard Y, Barrière G, Reigadas S, Vandenhende M-A, Bonnet F
Аннотация
OBJECTIVES: To characterize real-world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)-based regimens with a focus on treatment persistence, effectiveness (HIV-1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities.
METHODS: People living with HIV from the prospective ANRS-CO3-AquiVIH-NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC- or DTG-based regimen between 2018 and 2021, were eligible for analysis.
RESULTS: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53-56 years and a comorbidity prevalence of 71%-75% across treatment groups (chronic kidney disease (CKD) 15%-25%, diabetes mellitus 15%-19%, hypertension 57%-64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing-equals-excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD.
CONCLUSIONS: In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.
METHODS: People living with HIV from the prospective ANRS-CO3-AquiVIH-NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC- or DTG-based regimen between 2018 and 2021, were eligible for analysis.
RESULTS: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53-56 years and a comorbidity prevalence of 71%-75% across treatment groups (chronic kidney disease (CKD) 15%-25%, diabetes mellitus 15%-19%, hypertension 57%-64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing-equals-excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD.
CONCLUSIONS: In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.